Cepheid Reports 2009 Second Quart...(9 Investments ...),Health

Date:7/30/2009

9 Investments - 24,539 Other non-current assets 493 920 Intangible assets 34,235 33,791 Goodwill 18,626 18,556 ------ ------ Total assets $184,348 $183,979 ======== ======== LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $12,458 $9,669 Accrued compensation 8,187 7,919 Accrued royalties 7,122 5,953 Accrued collaboration profit sharing 872 2,023 Accrued other liabilities 7,495 6,816 Current portion of deferred revenue 2,753 2,834 Bank borrowing 14,598 14,639 ------ ------ Total current liabilities 53,485 49,853 Long-term portion of deferred revenue 1,840 1,753 Other liabilities 4,641 3,549 ----- ----- Total liabilities 59,966 55,155 ------ ------ Shareholders' equity: Common stock 269,374 266,991 Additional paid-in capital 49,117 41,619 Accumulated other comprehensive income (loss) 35 (23) Accumul
'/>"/>

SOURCE Cepheid Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results